Partial oral antibiotic treatment of endocarditis in patients who inject drugs: a case series

Abstract Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in person...

Full description

Saved in:
Bibliographic Details
Published inJAC-antimicrobial resistance Vol. 4; no. 1; p. dlac008
Main Authors Miller, Kaylie, Evans, Emily, Sheridan, Kathleen R., Nauriyal, Varidhi, Viehman, J. Alexander, Rivosecchi, Ryan, Stoner, Bobbi Jo, El-Dalati, Sami
Format Journal Article
LanguageEnglish
Published England Oxford University Press 01.03.2022
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs. Objectives To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy. Methods Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution’s multidisciplinary endocarditis team. Results In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge. Conclusions These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs.
AbstractList Abstract Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs. Objectives To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy. Methods Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution’s multidisciplinary endocarditis team. Results In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge. Conclusions These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs.
Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs. To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy. Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution's multidisciplinary endocarditis team. In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge. These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs.
Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs.BACKGROUNDRecent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs.To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy.OBJECTIVESTo evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy.Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution's multidisciplinary endocarditis team.METHODSConsecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution's multidisciplinary endocarditis team.In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge.RESULTSIn 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge.These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs.CONCLUSIONSThese data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs.
Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite the rising incidence of injection drug use-related endocarditis, partial oral therapy has not been well studied in persons who inject drugs. Objectives To evaluate the rate of relapsed infection and 90 day mortality in patients with infectious endocarditis treated with partial oral antibiotic therapy. Methods Consecutive patients with infectious endocarditis treated with partial oral antibiotic therapy were identified by study investigators and reviewed by independent clinicians. The decision to use partial oral antibiotic therapy was made by the institution’s multidisciplinary endocarditis team. Results In 11 cases of infective endocarditis treated with partial oral antibiotic therapy, 9 of which were complicated by injection drug use, there were no relapsed infections with the primary organism. Five patients underwent surgical valve replacement, and the median duration of oral antibiotic therapy was 23 days. All patients survived to in-hospital discharge and 90 days post-discharge. Ten patients followed up with an infectious diseases provider after discharge. Conclusions These data add to existing literature demonstrating non-inferior outcomes with partial oral antibiotic treatment when compared with IV antibiotic treatment alone in patients with endocarditis, including persons who inject drugs.
Author Stoner, Bobbi Jo
Sheridan, Kathleen R.
Rivosecchi, Ryan
Viehman, J. Alexander
Miller, Kaylie
Nauriyal, Varidhi
Evans, Emily
El-Dalati, Sami
AuthorAffiliation 1 University of Pittsburgh Medical Center , Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA
4 University of Kentucky Medical Center , Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street Lexington, KY 40536, USA
2 University of Pittsburgh Medical Center , Division of Infectious Diseases, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA
3 University of Pittsburgh Medical Center , Department of Pharmacy, 3501 Terrace Street Pittsburgh, PA 15213, USA
AuthorAffiliation_xml – name: 3 University of Pittsburgh Medical Center , Department of Pharmacy, 3501 Terrace Street Pittsburgh, PA 15213, USA
– name: 4 University of Kentucky Medical Center , Division of Infectious Diseases, Department of Internal Medicine, 740 S. Limestone Street Lexington, KY 40536, USA
– name: 1 University of Pittsburgh Medical Center , Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA
– name: 2 University of Pittsburgh Medical Center , Division of Infectious Diseases, Department of Internal Medicine, 3601 Fifth Avenue Pittsburgh, PA 15213, USA
Author_xml – sequence: 1
  givenname: Kaylie
  surname: Miller
  fullname: Miller, Kaylie
– sequence: 2
  givenname: Emily
  surname: Evans
  fullname: Evans, Emily
– sequence: 3
  givenname: Kathleen R.
  surname: Sheridan
  fullname: Sheridan, Kathleen R.
– sequence: 4
  givenname: Varidhi
  surname: Nauriyal
  fullname: Nauriyal, Varidhi
– sequence: 5
  givenname: J. Alexander
  surname: Viehman
  fullname: Viehman, J. Alexander
– sequence: 6
  givenname: Ryan
  surname: Rivosecchi
  fullname: Rivosecchi, Ryan
– sequence: 7
  givenname: Bobbi Jo
  surname: Stoner
  fullname: Stoner, Bobbi Jo
– sequence: 8
  givenname: Sami
  orcidid: 0000-0003-2603-2951
  surname: El-Dalati
  fullname: El-Dalati, Sami
  email: s.eldalati10@gmail.com
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35156032$$D View this record in MEDLINE/PubMed
BookMark eNqFUUtrFTEYDdJia-3WpQTc6OK2eczk4UKQYrVQ0IUuJXyTSdpcZpJrklH896bc29IWpJs8-M45OSfnBdqLKTqEXlFyQonmp2uwMOfTcQJLiHqGDpngbEUV43v3zgfouJQ1IYT1RHaSPUcHvKe9IJwdop_fINcAE065LRBrGEKqweKaHdTZxYqTxy6OyUIeQw0Fh4g3UEMbFfznOrX72tmKx7xclfcYsIXicHE5uPIS7XuYijve7Ufox_mn72dfVpdfP1-cfbxc2a7TdaVHrkdPAbztRt9pGLjrVd9554XUXmg6gBZSci0sZYIMwgkidcelGjqqLT9CH7a6m2WY3WibtxbHbHKYIf81CYJ5OInh2lyl30YpJvteN4G3O4Gcfi2uVDOHYt00QXRpKYYJpoQSXPQN-uYRdJ2WHFs8w6nQWkmhaEO9vu_ozsrtzzfAyRZgcyolO38HocTctGu27Zpdu43QPSLYUFsP6SZRmP5Pe7elpWXz1BP_ACX3uwg
CitedBy_id crossref_primary_10_1093_jacamr_dlaf032
crossref_primary_10_1016_j_cmi_2023_04_005
crossref_primary_10_1093_cid_ciac714
Cites_doi 10.1016/j.idc.2020.06.010
10.1093/ofid/ofz089
10.1093/ofid/ofy132
10.1086/313753
10.1161/CIR.0000000000000296
10.1093/cid/ciaa365
10.1097/ADM.0000000000000693
10.1111/j.1470-9465.2004.00846.x
10.1056/NEJMoa1808312
10.1093/cid/ciaa1126
10.1093/ejcts/ezy325
ContentType Journal Article
Copyright The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2022
The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. 2022
– notice: The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
– notice: The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy. This work is published under https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID TOX
AAYXX
CITATION
NPM
3V.
7X7
7XB
8C1
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOI 10.1093/jacamr/dlac008
DatabaseName Oxford Journals Open Access (Activated by CARLI)
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Public Health Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Public Health
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: TOX
  name: Oxford Journals Open Access Collection
  url: https://academic.oup.com/journals/
  sourceTypes: Publisher
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2632-1823
ExternalDocumentID PMC8827559
35156032
10_1093_jacamr_dlac008
10.1093/jacamr/dlac008
Genre Journal Article
GroupedDBID 0R~
53G
AAFWJ
AAPXW
AAVAP
ABPTD
ABXVV
AFPKN
AFULF
ALMA_UNASSIGNED_HOLDINGS
EBS
GROUPED_DOAJ
IAO
IHR
INH
KSI
M~E
OK1
ROX
RPM
TOX
7X7
8C1
8FI
8FJ
AAYXX
ABEJV
ABGNP
ABUWG
AFKRA
AMNDL
BENPR
CCPQU
CITATION
FYUFA
HMCUK
ITC
PHGZM
PHGZT
PIMPY
UKHRP
NPM
3V.
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c449t-9d39df1aafc4df49ab3e5854fef679f691ba9677396c1260b6e60794378b419c3
IEDL.DBID 7X7
ISSN 2632-1823
IngestDate Thu Aug 21 18:13:57 EDT 2025
Fri Jul 11 06:45:02 EDT 2025
Fri Jul 25 21:51:25 EDT 2025
Wed Feb 19 02:26:57 EST 2025
Tue Jul 01 03:54:18 EDT 2025
Thu Apr 24 23:05:02 EDT 2025
Wed Aug 28 03:17:26 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
https://creativecommons.org/licenses/by-nc/4.0
The Author(s) 2022. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c449t-9d39df1aafc4df49ab3e5854fef679f691ba9677396c1260b6e60794378b419c3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-2603-2951
OpenAccessLink https://www.proquest.com/docview/3169987681?pq-origsite=%requestingapplication%
PMID 35156032
PQID 3169987681
PQPubID 7097363
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8827559
proquest_miscellaneous_2628686365
proquest_journals_3169987681
pubmed_primary_35156032
crossref_primary_10_1093_jacamr_dlac008
crossref_citationtrail_10_1093_jacamr_dlac008
oup_primary_10_1093_jacamr_dlac008
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-Mar
PublicationDateYYYYMMDD 2022-03-01
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-Mar
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Oxford
PublicationTitle JAC-antimicrobial resistance
PublicationTitleAlternate JAC Antimicrob Resist
PublicationYear 2022
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Rapoport (2022031017575820000_dlac008-B6) 2018; 5
Kimmel (2022031017575820000_dlac008-B10) 2021; 15
Marks (2022031017575820000_dlac008-B3) 2020; 71
Serota (2022031017575820000_dlac008-B5) 2020; 34
Perea (2022031017575820000_dlac008-B8) 2004; 10
Rao (2022031017575820000_dlac008-B9) 2019; 55
Baddour (2022031017575820000_dlac008-B1) 2015; 132
Leahey (2022031017575820000_dlac008-B4) 2019; 6
Iversen (2022031017575820000_dlac008-B2) 2019; 380
Li (2022031017575820000_dlac008-B7) 2000; 30
Kimmel (2022031017575820000_dlac008-B11) 2021; 73
References_xml – volume: 34
  start-page: 539
  year: 2020
  ident: 2022031017575820000_dlac008-B5
  article-title: Applying the infectious diseases literature to people who inject drugs
  publication-title: Infect Dis Clin North Am
  doi: 10.1016/j.idc.2020.06.010
– volume: 6
  start-page: ofz089
  year: 2019
  ident: 2022031017575820000_dlac008-B4
  article-title: High morbidity and mortality among patients with sentinel admission for injection drug use-related infective endocarditis
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofz089
– volume: 5
  start-page: ofy132
  year: 2018
  ident: 2022031017575820000_dlac008-B6
  article-title: Infectious diseases physicians’ perspectives regarding injection drug use and related infections, United States, 2017
  publication-title: Open Forum Infect Dis
  doi: 10.1093/ofid/ofy132
– volume: 30
  start-page: 633
  year: 2000
  ident: 2022031017575820000_dlac008-B7
  article-title: Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis
  publication-title: Clin Infect Dis
  doi: 10.1086/313753
– volume: 132
  start-page: 1435
  year: 2015
  ident: 2022031017575820000_dlac008-B1
  article-title: Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association
  publication-title: Circulation
  doi: 10.1161/CIR.0000000000000296
– volume: 71
  start-page: e650–6
  year: 2020
  ident: 2022031017575820000_dlac008-B3
  article-title: Evaluation of partial oral antibiotic treatment for persons who inject drugs and are hospitalized with invasive infections
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa365
– volume: 15
  start-page: 20
  year: 2021
  ident: 2022031017575820000_dlac008-B10
  article-title: Rejection of patients with opioid use disorder referred for post-acute medical care before and after an anti-discrimination settlement in Massachusetts
  publication-title: J Addict Med
  doi: 10.1097/ADM.0000000000000693
– volume: 10
  start-page: 96
  issue: Suppl 1
  year: 2004
  ident: 2022031017575820000_dlac008-B8
  article-title: Oral versus intravenous therapy in the treatment of systemic mycosis
  publication-title: Clin Microbiol Infect
  doi: 10.1111/j.1470-9465.2004.00846.x
– volume: 380
  start-page: 415
  year: 2019
  ident: 2022031017575820000_dlac008-B2
  article-title: Partial oral versus intravenous antibiotic treatment of endocarditis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1808312
– volume: 73
  start-page: e2484–92
  year: 2021
  ident: 2022031017575820000_dlac008-B11
  article-title: Against medical advice discharges in injection and non-injection drug use-associated infective endocarditis: a nationwide cohort study
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciaa1126
– volume: 55
  start-page: 760
  year: 2019
  ident: 2022031017575820000_dlac008-B9
  article-title: Impact of the duration of antibiotic therapy on relapse and survival following surgery for active infective endocarditis
  publication-title: Eur J Cardiothorac Surg
  doi: 10.1093/ejcts/ezy325
SSID ssj0002507472
Score 2.196992
Snippet Abstract Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in...
Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select patients. Despite...
Background Recent literature has demonstrated that partial oral antibiotic treatment of infectious endocarditis is non-inferior to IV therapy in select...
SourceID pubmedcentral
proquest
pubmed
crossref
oup
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage dlac008
SubjectTerms Antibiotics
Drug use
Endocarditis
Original
Title Partial oral antibiotic treatment of endocarditis in patients who inject drugs: a case series
URI https://www.ncbi.nlm.nih.gov/pubmed/35156032
https://www.proquest.com/docview/3169987681
https://www.proquest.com/docview/2628686365
https://pubmed.ncbi.nlm.nih.gov/PMC8827559
Volume 4
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3da9RAEB-0RfBF_Da1HqsIPoW7ZDe7WV9ES0sRrEVauBcJm81uG6lJe7lD_O-dSfbinaC-LIRMSLIzu_OxM78BeJ3NuPGoyGJrfRWT_4Vrztk4TbwwpclFOqNq5E8n8vhcfJxn8xBw60Ja5XpP7DfqqrUUI5_yRKJngMZx8u76JqauUXS6Glpo3IZdgi4jqVZzNcZYUL2jtZyOWI18-s1Y830xra6MnVFHyQ1dtFXftmFm_pktuaF-ju7DvWA3svcDox_ALdc8hDtDJ8mfj-DrKYkAElDBPcPZqsu6RVI2JpKz1jPX4H-SSCzrjtUNC6CqHftx2eI1hWRYtVhddG-ZYRb1GyMBdd1jOD86PDs4jkPnhNgKoZexrriufGKMt6LyQpuSO_QLhHdeKu2lTkqjpVJcS5ugR1NKJ2cEFafyUiTa8iew07SNewbMo_LipcqzTAlRSpGnPrMpPqisJWMvgng9h4UNsOLU3eKqGI63eTHMeRHmPII3I_31AKjxV8pXyJL_Eu2vOVaE1dcVv2UlgpfjbVw3dBhiGteuuiKlmtxccplF8HRg8PgqnlF9OU8jUFusHwkIk3v7TlNf9tjc6LAodNL2_v1Zz-FuSmUUfS7bPuwsFyv3Ao2bZTnpJRjH_CCZwO6Hw5PTL5M-UIDj2ef5L6E5Ajc
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VIgQviJtAAYNAPEW7sR07QUIIFaotPcRDK_UFpY5j06CSlM2uqv4pfiMzm4NdJOCpj5Enh-bIfGPPAfAyHgvj0ZGF1voipPgLbc7ZkEdemtwkko-pGnlvX00O5aej-GgNfva1MJRW2f8TFz_qora0Rz4SkcLIAMFx9O7sR0hTo-h0tR-h0arFjrs4x5Ctebv9AeX7ivOtjwebk7CbKhBaKdNZmBYiLXxkjLey8DI1uXCImaV3XunUqzTKTaq0FqmyEaL9XDk1pjZqOslllFqBz70CV6VA06TK9M1o2NNBOIHonA-9IcXom7Hm-3RUnBo7pgmWS75vpZ5uCdb-mZ255O62bsHNDqey961i3YY1V92Ba-3kyou78OUzqRwSUIE_Q-mUeVkjKRsS11ntmauQr6SCs7JhZcW6Jq4NOz-p8Zq2gFgxnX9t3jDDLPpTRgbhmntweCk8vQ_rVV25h8A8OkuR6ySOtZS5kgn3seV4o7aWwGUAYc_DzHZtzGmaxmnWHqeLrOV51vE8gNcD_VnbwOOvlC9QJP8l2ugllnXW3mS_dTOA58My2ikdvpjK1fMm41QDnCih4gAetAIeXiViqmcXPAC9IvqBgHqAr65U5cmiFzgGSBqDwkf__qxncH1ysLeb7W7v7zyGG5xKOBZ5dBuwPpvO3RMEVrP86UKbGRxftvn8Am-POjY
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Partial+oral+antibiotic+treatment+of+endocarditis+in+patients+who+inject+drugs%3A+a+case+series&rft.jtitle=JAC-antimicrobial+resistance&rft.au=Miller%2C+Kaylie&rft.au=Evans%2C+Emily&rft.au=Sheridan%2C+Kathleen+R.&rft.au=Nauriyal%2C+Varidhi&rft.date=2022-03-01&rft.pub=Oxford+University+Press&rft.eissn=2632-1823&rft.volume=4&rft.issue=1&rft_id=info:doi/10.1093%2Fjacamr%2Fdlac008&rft.externalDocID=10.1093%2Fjacamr%2Fdlac008
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2632-1823&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2632-1823&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2632-1823&client=summon